Femasys (FEMY) Other Non-Current Liabilities (2020 - 2026)
Femasys' (FEMY) quarterly Other Non-Current Liabilities came in at $1.3 million in Q1 2026, down 32.26% YoY from $1.9 million in Q1 2025, and down 75.98% on a QoQ basis from $5.2 million in Q4 2025.
Femasys (FEMY) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Femasys (FEMY) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 32.26% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 32.26% YoY) and the FY2025 annual result came in at $5.2 million, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $1.3 million in Q1 2026, from $5.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $6.7 million in Q3 2025 to a low of $567972.0 in Q2 2022.
- A 5-year average of $2.1 million and a median of $1.8 million in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities soared 390.72% — and 2026, when it sank 32.26%.
- Tracing FEMY's Other Non-Current Liabilities over 5 years: stood at $567972.0 in 2022, then soared by 390.72% to $2.8 million in 2023, then fell by 6.4% to $2.6 million in 2024, then jumped by 101.11% to $5.2 million in 2025, then plunged by 75.98% to $1.3 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.3 million (Q1 2026), $5.2 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Femasys | 9.97 Mn | 8.53 Mn | 189,391.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 5.25 Mn |
| Sep 30, 2025 | 6.73 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 567,972.00 |
| Dec 31, 2022 | 567,972.00 |
| Sep 30, 2022 | 567,972.00 |
| Jun 30, 2022 | 567,972.00 |
| Mar 31, 2022 | 702,492.00 |
| Dec 31, 2021 | 702,492.00 |
| Sep 30, 2021 | 702,492.00 |
| Jun 30, 2021 | 702,492.00 |
| Dec 31, 2020 | 32,895.00 |